These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35246104)

  • 1. The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients.
    Ye S; Wang Y; Chen L; Wu X; Yang H; Xiang L
    BMC Surg; 2022 Mar; 22(1):81. PubMed ID: 35246104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer.
    Son JH; Kong TW; Paek J; Chang SJ; Ryu HS
    J Surg Oncol; 2019 Jun; 119(7):1011-1015. PubMed ID: 30737795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
    Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
    Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Grimm C; Harter P; Alesina PF; Prader S; Schneider S; Ataseven B; Meier B; Brunkhorst V; Hinrichs J; Kurzeder C; Heitz F; Kahl A; Traut A; Groeben HT; Walz M; du Bois A
    Gynecol Oncol; 2017 Sep; 146(3):498-503. PubMed ID: 28610745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
    Mourton SM; Temple LK; Abu-Rustum NR; Gemignani ML; Sonoda Y; Bochner BH; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Dec; 99(3):608-14. PubMed ID: 16153697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.
    Ye S; He T; Liang S; Chen X; Wu X; Yang H; Xiang L
    BMC Cancer; 2017 May; 17(1):317. PubMed ID: 28476108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Plett H; Filippova OT; Garbi A; Kommoss S; Rosendahl M; Langstraat C; Phadnis S; Muallem MZ; Baert T; Chi DS; Aletti GD; Taran FA; Ramspott JP; Zivanovic O; du Bois A; Sonoda Y; Gardner G; Traut A; Roche KL; Harter P
    Gynecol Oncol; 2020 Nov; 159(2):434-441. PubMed ID: 32919778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer.
    Derlatka P; Sienko J; Grabowska-Derlatka L; Palczewski P; Danska-Bidzinska A; Bidzinski M; Czajkowski K
    World J Surg Oncol; 2016 Feb; 14():58. PubMed ID: 26923029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study.
    Matak L; Mikuš M; Ćorić M; Spagnol G; Matak M; Vujić G
    Arch Gynecol Obstet; 2023 Jul; 308(1):231-237. PubMed ID: 36680573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer.
    Tozzi R; Casarin J; Baysal A; Valenti G; Kilic Y; Majd HS; Morotti M
    J Gynecol Oncol; 2019 Mar; 30(2):e25. PubMed ID: 30740956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Nica A; Covens A; Parra-Herran C; May T
    Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectosigmoid resection morbidity in ovarian cancer cytoreductive surgery.
    Usmani AS; Yasin I; Asif RB; Khalid N; Syed AA
    J Pak Med Assoc; 2023 Jun; 73(6):1284-1287. PubMed ID: 37427631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis.
    Fournier M; Huchon C; Ngo C; Bensaid C; Bats AS; Combe P; le FrèreBelda MA; Fournier L; Berger A; Lecuru F
    Eur J Surg Oncol; 2018 Jun; 44(6):750-753. PubMed ID: 29580734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes.
    Erkilinç S; Karataşli V; Demir B; Çakir İ; Can B; Karadeniz T; Gökçü M; Sanci M
    Int J Gynecol Cancer; 2018 Nov; 28(9):1699-1705. PubMed ID: 30371561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer.
    Leitao MM; Iasonos A; Tomberlin M; Moukarzel LA; Price H; Bennetti G; Ramesh B; Chi DS; Long Roche K; Sonoda Y; Al-Niami A; Mueller JJ; Gardner GJ; Broach V; Jewell EL; Kim S; Feinberg J; Abu-Rustum NR; Zivanovic O
    Int J Gynecol Cancer; 2024 Jul; 34(7):1098-1101. PubMed ID: 38514101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.